Therefore, we hypothesized that high level expression of AKR1B10 would suppress CRC development via a non-canonical FGF1-dependent pathway, and our findings demonstrated a novel role of AKR1B10 in CRC and identified its potential diagnostic and therapeutic relevance. This evidence concerns the gene FGF1 and colorectal carcinoma.